Great ann by VHL: Virax Completes Acquisition of US Specialty Oncology Company and Novel Cancer Drug Candidate HIGHLIGHTS ? Pathway Oncology acquisition finalised with Virax taking exclusive worldwide license to valuable drug candidate GGTI-2418 ? Virax becomes mid-clinical stage oncology company, with Phase 2 clinical program expected 2015/16 ? Overwhelming shareholder support for all scrip acquisition to be paid in three tranches ? High calibre international biotechnology executive Paul Hopper joins board as executive director
